ARTL
Artelo Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.91
−4.98%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 3.8M | 5.4M | 6.0M | 5.7M | 4.3M |
| SG&A Expense | 7.3M | 6.0M | 4.1M | 4.2M | 6.0M |
| General & Admin Expense | 7.3M | 6.0M | 4.1M | 4.2M | 6.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 11.1M | 11.4M | 10.1M | 9.9M | 10.3M |
| Cost and Expenses | 11.1M | 11.4M | 10.1M | 9.9M | 10.3M |
| Operating Income (EBIT) | (11.1M) | (11.4M) | (10.1M) | (9.9M) | (10.3M) |
| Non-Operating | |||||
| Interest Income | 61.0K | — | — | — | 2.0K |
| Interest Expense | 618.0K | 194.0K | — | — | 5.0K |
| Net Interest Income | (557.0K) | (194.0K) | — | — | (3.0K) |
| Other Non-Op Income/Expense | (1.6M) | (1.5M) | 282.0K | 641.0K | 204.0K |
| Non-Operating Income (excl Interest) | 984.0K | 1.3M | (282.0K) | (641.0K) | (209.0K) |
| EBT (Pre-Tax Income) | (12.7M) | (12.9M) | (9.8M) | (9.3M) | (10.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (12.7M) | (12.9M) | (9.8M) | (9.3M) | (10.1M) |
| Earnings from Cont. Ops | (12.7M) | (12.9M) | (9.8M) | (9.3M) | (10.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (12.7M) | (12.9M) | (9.8M) | (9.3M) | (10.1M) |
| Per Share | |||||
| Basic EPS | ($74.28) | ($49.23) | ($9.15) | ($9.42) | ($10.47) |
| Diluted EPS | ($74.28) | ($49.23) | ($9.15) | ($9.42) | ($10.47) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 301333 | 261832 | 1.1M | 986667 | 157333 |
| Diluted Shares Outstanding | 301333 | 261832 | 1.1M | 986667 | 157388 |
| Profitability Metrics | |||||
| EBITDA | (12.1M) | (12.5M) | (9.8M) | (9.3M) | (10.1M) |
| D&A | — | 146.0K | — | — | — |
| EBIT | (12.1M) | (12.7M) | (9.8M) | (9.3M) | (10.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026